Endo Pharmaceuticals dropped out as SkyePharma plc's North American development partner for Propofol IDD-D, leaving the future of the anesthetic in limbo as the London-based company decides the next steps. (BioWorld Today)

Three months after announcing a restructuring plan to focus only on molecular diagnostics and proteomics, Celera Genomics Group sold several small-molecule drug candidates to Pharmacyclics Inc. in a deal worth up to $150 million in up-front, equity and milestone payments. (BioWorld Today)

To move its lead cancer product into Phase II trials, Tapestry Pharmaceuticals Inc. closed a $25.5 million private placement with nine institutional investors. (BioWorld Today)